Innate Pharma (OTCMKTS:IPHYF – Get Free Report) is expected to announce its results before the market opens on Thursday, September 17th. Analysts expect Innate Pharma to announce earnings of ($0.2912) per share and revenue of $6.2810 million for the quarter.
Innate Pharma Stock Performance
Shares of IPHYF opened at $1.65 on Tuesday. Innate Pharma has a 52-week low of $1.37 and a 52-week high of $2.25. The company has a 50-day simple moving average of $1.65 and a 200-day simple moving average of $1.70.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Further Reading
- Five stocks we like better than Innate Pharma
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
